MYOV - Myovant Sciences: Bull And Bear Cases And Investment Decision
Myovant Sciences (MYOV) was founded in 2016 and is based in Brisbane, CA, and Basel, Switzerland. The company's pipeline is focused on the diseases of women's health. The key flagship molecule is Relugolix, a direct antagonist of Gonadotropin-releasing hormone, GnRH. It is already available in Japan as a monotherapy for treating bleeding due to uterine fibroids (marketed by Takeda). Myovant licensed it from Takeda for various indications outside Japan and certain other Asian territories.
Near-term catalysts:
- Phase 3 data for Relugolix (SPIRIT 2 trial) in treating endometriosis-associated pain in Q1 2020.
- MAA filing